COMP <GO>
CLYM vs NGNE // OPERATING MARGIN
Climb Bio Inc. (NASDAQ) VS. Neurogene Inc. (NASDAQ) • 15-METRIC TALLY: CLYM 3
— NGNE 1
■ METRIC PARITY
LAST: $10.33 (+2.08%) • MKT CAP: $593.3M
operating-margins
—
LAST: $28.82 (-5.26%) • MKT CAP: $576.7M
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLYM VS. NGNE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLYM | NGNE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.19% | -13.59% | +4.40 | CLYM | /fcf-yield <GO> |
| Operating Margin ACTIVE | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 12.76 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | CLYM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.1 | 51.0 | -6.86 | NGNE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $593.3M | $576.7M | $16.6M | CLYM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLYM REV | NGNE REV | CLYM GROSS % | NGNE GROSS % | CLYM FCF | NGNE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$54.5M | -$78.4M |
| FY 2024 | $0 | $925.0K | — | — | -$15.6M | -$71.4M |
| FY 2023 | $0 | $0 | — | — | -$20.6M | -$51.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLYM // BETA —
NGNE // BETA —